Possible Solution for Parkinson's Levodopa Therapy Biology Essay
Introduction. Parkinson's disease was first described by Dr. James Parkinson in his article entitled 'Essay on the shaking palsy'. The prevalence of Parkinson's has increased faster than many other neurodegenerative disorders. Global prevalence is expected to double to one million, million. Since its first introduction: levodopa has become the cornerstone for the treatment of Parkinson's disease and remains the main therapeutic choice for motor control therapy to date; After more years of clinical use, levodopa LD remains the gold standard for symptomatic efficacy in the drug treatment of Parkinson's disease. Compared to other available dopaminergic therapies, dopamine replacement with LD is associated with the greatest improvement in motor function. Long-term treatment with levodopa-induced dyskinesias. LIDs are a disabling side effect of long-term use of levodopa therapy and negatively impact the quality of life in people with Parkinson's disease. From the Greek word dys, meaning sick or bad, and kīnēsia, meaning movement or muscle activity, dyskinesias are abnormal. As natural dopamine levels in the brain begin to decline, signs of Parkinson's disease appear. When dopamine is replaced, many of the symptoms improve. So you would think that dopamine should be given as quickly as possible. However, there are other options. In addition to directly administering dopamine, a drug called carbidopalevodopa Parkinson is also administered. Parkinson's disease is a slowly progressive, incurable, neurodegenerative disorder with progressive motor symptoms that can be controlled with treatments. Levodopa is widely recognized as the most effective and widely used treatment for Parkinson's. It improves function and quality of life, morbidity and mortality, thereby reducing Levodopa-induced dyskinesia. LID is an adverse effect that negatively impacts the quality of life of patients with Parkinson's disease. Studies report that genetic variations in the genes of the levodopa L-DOPA pharmacogenetic pathway may be associated with the development of LID. The aim of the current study was to make Levodopa the gold standard drug for the treatment of Parkinson's disease, improving the quality of life, quality of life and life expectancy of the patient population for several years through its effectiveness in improving of motor symptoms 1,2, 3,4,5. The superior efficacy of levodopa was suggested by the real-world PD-MED study, which showed that in,